https://wikimd.org/index.php?action=history&feed=atom&title=Alpha-synucleinAlpha-synuclein - Revision history2026-05-13T13:16:08ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Alpha-synuclein&diff=5631503&oldid=prevPrab: CSV import2024-04-19T14:53:37Z<p>CSV import</p>
<p><b>New page</b></p><div>[[File:Lewy_bodies_(alpha_synuclein_inclusions).svg|Lewy bodies (alpha synuclein inclusions)|thumb]] [[File:Lewy_Body_alphaSynuclein.jpg|Lewy Body alphaSynuclein|thumb|left]] [[File:Events_in_alpha_synuclein_toxicity.jpg|Events in alpha synuclein toxicity|thumb|left]] '''Alpha-synuclein''' is a [[protein]] that, in humans, is encoded by the ''SNCA'' gene. It is predominantly expressed in the [[brain]], particularly in the [[neuron]]s, and is involved in various [[neurological]] processes. Notably, alpha-synuclein plays a significant role in the regulation of [[dopamine]] release and transport. It is best known for its association with [[Parkinson's disease]] and other related [[neurodegenerative disorders]], such as [[multiple system atrophy]] and [[dementia with Lewy bodies]].<br />
<br />
==Structure and Function==<br />
Alpha-synuclein is a small, 140-amino acid protein that is natively unfolded; that is, it does not have a fixed or rigid three-dimensional structure. This lack of structure allows it to interact with a variety of [[biological molecules]], playing roles in several cellular processes. Among its functions, alpha-synuclein is involved in synaptic vesicle regulation and [[neurotransmitter]] release, contributing to the normal operation of [[neuronal communication]].<br />
<br />
==Pathology==<br />
The aggregation of alpha-synuclein into fibrils forming insoluble [[Lewy bodies]] is a hallmark of several neurodegenerative diseases, collectively known as [[synucleinopathies]]. In Parkinson's disease, the accumulation of Lewy bodies in the [[substantia nigra]], a region of the brain involved in movement control, leads to the degeneration of neurons and the characteristic symptoms of the disease, such as [[bradykinesia]], [[rigidity]], and [[tremor]].<br />
<br />
Mutations in the ''SNCA'' gene, such as the A53T and E46K mutations, have been linked to familial forms of Parkinson's disease, suggesting a genetic component to the disorder. Additionally, duplication or triplication of the ''SNCA'' gene can increase the expression of alpha-synuclein, leading to an early onset of the disease.<br />
<br />
==Research and Therapeutic Approaches==<br />
Research into alpha-synuclein has focused on understanding its role in neurodegeneration and developing therapeutic strategies to prevent its aggregation. Approaches include small molecules that inhibit aggregation, immunotherapy targeting alpha-synuclein aggregates, and gene therapy aimed at reducing ''SNCA'' gene expression. These strategies are in various stages of research and clinical trials, offering hope for new treatments for Parkinson's disease and other synucleinopathies.<br />
<br />
==See Also==<br />
* [[Parkinson's disease]]<br />
* [[Neurodegeneration]]<br />
* [[Lewy body]]<br />
* [[Synucleinopathy]]<br />
* [[Neurotransmitter]]<br />
<br />
[[Category:Proteins]]<br />
[[Category:Neurodegenerative disorders]]<br />
{{medicine-stub}}</div>Prab